Chimeric Therapeutics Ltd has released a press release.
Strategic manufacturing partnership with WuXi ATU
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Security Class Reinstatement to Quotation CHMO
- CDH17 car t preclinical data featured in nature cancer
- Completion of retail component of Entitlement Offer
- Security Class Suspension from Quotation CHMO
- Final Results in Phase 1 Trial of CORE NK Platform
Later from Chimeric Therapeutics
- A$30 million Equity Placement Agreement with L1 Capital
- Licenses viral vector technology from Penn for CDH17
- Patent received in Japan for CLTX CAR technology
- Exclusive license agreement with CWRU for CORE-NK platform
- Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trial
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics